Financial Performance - The company reported a net loss of $20.148 million for the three months ended September 30, 2025, compared to a net loss of $23.156 million for the same period in 2024, reflecting a decrease in losses of approximately 13.1%[145] - Total operating expenses for the three months ended September 30, 2025, were $25.096 million, down from $27.068 million in 2024, indicating a reduction of about 7.3%[145] - The company reported a net loss of $74.0 million for the nine months ended September 30, 2025, compared to a net loss of $65.8 million in the same period of 2024[167][168] Research and Development - Research and development expenses decreased to $18.225 million in Q3 2025 from $21.258 million in Q3 2024, a decline of approximately 14.3%[145] - Research and development expenses for Q3 2025 were $18.2 million, a decrease of $3.1 million from $21.3 million in Q3 2024, primarily due to a $6.1 million decrease in ELVN-002 costs[147] - Research and development expenses for the nine months ended September 30, 2025, were $64.6 million, an increase of $4.5 million from $60.1 million in 2024, driven by higher internal costs[151] Cash and Liquidity - The company had cash, cash equivalents, and marketable securities totaling $477.6 million as of September 30, 2025, which is expected to fund operations for at least the next 12 months[128] - The company expects to require substantial additional capital to fund ongoing operations and product development, with existing resources projected to last at least 12 months[163] - Cash, cash equivalents, and marketable securities as of September 30, 2025, primarily consisted of U.S. Treasury securities and U.S. Treasury-backed money market funds[178] Operating Expenses - General and administrative expenses for Q3 2025 increased to $6.9 million from $5.8 million in Q3 2024, an increase of $1.1 million attributed to higher stock-based compensation[148] - General and administrative expenses for the nine months ended September 30, 2025, rose to $20.8 million from $17.6 million in 2024, reflecting a $3.2 million increase in stock-based compensation[152] - Total operating expenses for the nine months ended September 30, 2025, were $85.4 million, compared to $77.7 million for the same period in 2024, resulting in a net loss of $74.0 million[150] Financing Activities - The company raised aggregate gross proceeds of $90.0 million from a private placement in March 2024 and $230.0 million from a public offering in June 2025[127] - The company has raised a total of $230.0 million from public offerings and private placements since February 2023, with $40.0 million received through the Sales Agreement by September 30, 2025[154][158] - Net cash provided by financing activities rose to $218.2 million in 2025, up from $93.2 million in 2024, driven mainly by net proceeds from the sale of common stock and pre-funded warrants[171][172] Other Income and Expenses - Other income for Q3 2025 was $4.9 million, up from $3.9 million in Q3 2024, mainly due to a $1.1 million increase in interest income[149] - Other income for the nine months ended September 30, 2025, was $11.3 million, a decrease of $0.5 million from $11.8 million in 2024, primarily due to a lower gain related to the CVR liability[153] Debt and Lease Obligations - As of September 30, 2025, the company had no debt outstanding, eliminating exposure to interest rate risk related to debt[179] - The company entered into a non-cancellable operating lease for approximately 20,011 rentable square feet of office and laboratory space from January 1, 2025, through December 31, 2026[174] Strategic Initiatives - The company is advancing its ELVN-001 program into Phase 3 initiation expected in 2026, focusing on a highly selective active site inhibitor for CML[124] - The company plans to explore strategic alternatives for the ELVN-002 program and does not intend to pursue its development beyond 2025[123] Cash Flow Activities - Net cash used in operating activities for the nine months ended September 30, 2025 was $54.5 million, compared to $56.0 million for the same period in 2024, reflecting a decrease of 2.7%[167][168] - Net cash used in investing activities increased significantly to $186.2 million in 2025 from $36.7 million in 2024, primarily due to cash used to purchase marketable securities of $371.3 million[169][170] - The company experienced net cash outflows from changes in operating assets and liabilities of $2.3 million in 2025, compared to $4.0 million in 2024[167][168] Risk Management - The company has not engaged in any hedging activities to mitigate foreign currency exchange risk, although it may consider this in the future[180] - The company has entered into agreements with vendors for goods and services, which may include purchase obligations and termination obligations[174]

Financial Performance - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $477.6 million, providing a cash runway into the first half of 2029[9] - Research and development (R&D) expenses for Q3 2025 were $18.2 million, a decrease of 14.4% from $21.3 million in Q3 2024[9] - General and administrative (G&A) expenses for Q3 2025 were $6.9 million, an increase of 18.2% from $5.8 million in Q3 2024[9] - The company reported a net loss of $20.1 million for Q3 2025, compared to a net loss of $23.2 million for Q3 2024, reflecting a 13.4% improvement[9] - Total operating expenses for Q3 2025 were $25.1 million, a decrease from $27.1 million in Q3 2024[17] - The company had a weighted-average of 62,094 shares outstanding for Q3 2025, compared to 48,267 shares for Q3 2024[17] Clinical Trials and Research - The ENABLE trial of ELVN-001 in CML has completed the randomized Phase 1b portion and is on track to initiate a Phase 3 pivotal trial in 2026[3][4] - ELVN-001 is designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML)[4][10] - The company presented data from the ENABLE Phase 1a/1b clinical trial at multiple medical meetings, highlighting the strength of the data and the potential for ELVN-001[3][4] - The company plans to present additional data from the ENABLE trial at the 67th Annual American Society of Hematology (ASH) meeting in December 2025[5]

Group 1 - Enliven Therapeutics, Inc. (ELVN) shares have increased by 0.8% over the past four weeks, closing at $19.92, with a mean price target of $41.13 indicating a potential upside of 106.5% [1] - The average of eight short-term price targets ranges from a low of $33.00 to a high of $52.00, with a standard deviation of $6.66, suggesting a potential increase of 65.7% to 161% from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, with two estimates moving up in the last 30 days and the Zacks Consensus Estimate increasing by 8.8% [11][12] Group 2 - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - The consensus price target, while not entirely reliable, suggests a positive direction for price movement, which could guide further research into the stock's fundamentals [14]

Core Viewpoint - Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - For the fiscal year ending December 2025, Enliven Therapeutics is expected to earn -$1.95 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 15.2% over the past three months [8]. Institutional Investor Influence - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4][5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Enliven Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Enliven Therapeutics, Inc. (ELVN) shows significant upside potential with a mean price target of $41.13, indicating a 102.4% increase from its current trading price of $20.32 [1][2]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $6.66, suggesting variability in analyst predictions. The lowest estimate is $33.00 (62.4% increase), while the highest is $52.00 (155.9% increase) [2]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ELVN's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 5.3% over the last 30 days, with two estimates moving higher and no negative revisions [11][12]. - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside in the near term [13]. Caution on Price Targets - While price targets are often sought after by investors, they can be misleading. Empirical research suggests that price targets rarely indicate actual stock price movements, and analysts may set overly optimistic targets due to business incentives [7][8][10].

Core Insights - Enliven Therapeutics, Inc. announced the presentation of data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting [1] - The presentation will include both an oral and a poster session, showcasing the company's focus on chronic myeloid leukemia treatment [2] Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule therapeutics aimed at improving patient survival and overall well-being [3] - The company employs a precision oncology approach to address unmet medical needs, leveraging insights into clinically validated biological targets and innovative chemistry [3]

Financial Performance - The company reported total operating expenses of $28.584 million for the three months ended June 30, 2025, compared to $24.603 million for the same period in 2024, representing an increase of approximately 16.1%[142] - The net loss for the three months ended June 30, 2025, was $25.335 million, compared to a net loss of $19.950 million for the same period in 2024, reflecting an increase in losses of approximately 27%[142] - Total operating expenses for the six months ended June 30, 2025, were $60.3 million, compared to $50.6 million for the same period in 2024, reflecting a 19.5% increase[147] - The net loss for the six months ended June 30, 2025, was $53.9 million, compared to a net loss of $42.7 million in the same period of 2024, indicating a 26.2% increase in losses[147] - Other income decreased to $3.2 million for the three months ended June 30, 2025, down from $4.7 million in the same period of 2024, a decline of 31.9%[146] Research and Development - Research and development expenses were $21.491 million for the three months ended June 30, 2025, up from $18.826 million in 2024, indicating a year-over-year increase of about 8.9%[142] - The company is advancing its ELVN-001 program into Phase 3 initiation expected in 2026, while exploring strategic alternatives for the ELVN-002 program, which will not be developed beyond 2025[121] - The company plans to expand its pipeline of product candidates and continue to incur significant expenses associated with being a public company[140] - Research and development expenses increased to $21.5 million for the three months ended June 30, 2025, up from $18.8 million in the same period of 2024, representing a 14.3% increase[144] Cash and Capital - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $490.5 million, which is expected to fund operations for at least the next 12 months[125] - The company raised aggregate gross proceeds of $90.0 million from a private placement in March 2024 and $230.0 million from a public offering in June 2025[124] - The company plans to seek additional capital through equity or debt financings to support ongoing operations and product development[156] - Future capital requirements will depend on various factors, including the costs of research and development, regulatory review, and commercialization efforts[160] - Net cash provided by financing activities rose to $218.6 million in the first half of 2025, up from $92.1 million in 2024, driven by proceeds from the sale of common stock and pre-funded warrants[167][168] Expenses - General and administrative expenses increased to $7.093 million for the three months ended June 30, 2025, from $5.777 million in 2024, marking a rise of approximately 22.8%[142] - General and administrative expenses rose to $7.1 million for the three months ended June 30, 2025, compared to $5.8 million in the same period of 2024, marking a 22.4% increase[145] - Net cash used in operating activities for the six months ended June 30, 2025 was $41.2 million, compared to $43.8 million for the same period in 2024, reflecting a decrease of 6%[163][164] - Net cash used in investing activities increased significantly to $182.2 million in the first half of 2025 from $51.6 million in 2024, primarily due to cash used for purchasing marketable securities[165][166] Debt and Financial Risks - As of June 30, 2025, the company had no debt outstanding, mitigating exposure to interest rate risk[174] - The company does not currently hedge against foreign currency risks, although it has contracts denominated in foreign currencies[175] - A hypothetical 100 basis point change in interest rates would not have a material impact on the company's financial results due to the short-term nature of its investments[173] Accounting and Compliance - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future[132] - The company has not generated any revenue from product sales to date and does not expect to do so until regulatory approval is obtained[155] - The company has made no material changes to its critical accounting policies and estimates as of June 30, 2025[171] - The company has not engaged in any off-balance sheet arrangements during the reported periods[170] - The company entered into a non-cancellable operating lease for approximately 20,011 rentable square feet of office and laboratory space, with total lease obligations of $614,000 due by the end of 2026[169] - The company has an accumulated deficit of $297.4 million as of June 30, 2025, with significant losses incurred since inception, including net losses of $89.0 million and $71.6 million for the years ended December 31, 2024 and 2023, respectively[126]

[Company Overview and Q2 2025 Highlights](index=1&type=section&id=Company%20Overview%20and%20Q2%202025%20Highlights) This section provides an executive summary of Enliven Therapeutics' positive Phase 1 ELVN-001 trial data, strong financial position, and CEO commentary on future plans [Executive Summary](index=1&type=section&id=1.1%20Executive%20Summary) Enliven Therapeutics reported positive Phase 1 clinical trial data for ELVN-001 in CML, showing a 47% cumulative Major Molecular Response (MMR) rate and a favorable safety profile. The company maintains a strong financial position with $491 million in cash, providing a runway into the first half of 2029 - Enliven Therapeutics, a clinical-stage biopharmaceutical company, reported positive data from the Phase 1 clinical trial of ELVN-001 in CML[1](index=1&type=chunk) - The ELVN-001 trial showed a cumulative MMR rate of **47%**, with **32%** of patients achieving MMR by 24 weeks, and demonstrated a favorable safety and tolerability profile across all dose levels[1](index=1&type=chunk) Cash Position and Runway | Metric | Value | | :------------------------------------ | :--------------------------------------------------- | | Cash, cash equivalents, and marketable securities | $491 million | | Expected cash runway | Into the first half of 2029 | [CEO Commentary](index=1&type=section&id=1.2%20CEO%20Commentary) CEO Sam Kintz highlighted ELVN-001's differentiated efficacy and tolerability, positioning it as a potential best-in-class CML therapy, with a Phase 3 trial planned for 2026 and a strengthened balance sheet - CEO Sam Kintz stated that ELVN-001's differentiated efficacy, tolerability, and convenience position it to be a potential best-in-class therapy for CML[2](index=2&type=chunk) - The company expects to initiate its first Phase 3 pivotal trial for ELVN-001 in **2026**[2](index=2&type=chunk) - Enliven strengthened its balance sheet through a recent public offering that generated approximately **$230 million** in gross proceeds, extending its cash runway into the first half of **2029**[2](index=2&type=chunk) [Pipeline Updates: ELVN-001 Program](index=1&type=section&id=Pipeline%20Updates%3A%20ELVN-001%20Program) This section details the ELVN-001 program, including its mechanism of action, positive Phase 1 clinical trial results, and future development plans [ELVN-001 Program Description](index=1&type=section&id=2.1%20ELVN-001%20Program%20Description) ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to target the BCR::ABL gene fusion, the oncogenic driver for chronic myeloid leukemia (CML) - ELVN-001 is a potent, highly selective, small molecule kinase inhibitor[3](index=3&type=chunk) - It is designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML)[3](index=3&type=chunk) [ENABLE Phase 1 Clinical Trial Results](index=1&type=section&id=2.2%20ENABLE%20Phase%201%20Clinical%20Trial%20Results) Updated positive data from the ENABLE Phase 1 clinical trial for ELVN-001 in previously treated CML patients demonstrated a 47% cumulative Major Molecular Response (MMR) rate, favorable tolerability, and comparative efficacy - Positive updated data from the ongoing ENABLE Phase 1 clinical trial (NCT05304377) for ELVN-001 in previously treated CML patients were announced in June 2025[3](index=3&type=chunk) ELVN-001 ENABLE Phase 1 MMR Rates (as of April 28, 2025) | Metric | Rate | | :------------------------------------------------ | :--- | | Evaluated patients in Major Molecular Response (MMR) | 47% (25 of 53) | | Patients achieving MMR by 24 weeks | 32% (13 of 41) | | Patients maintaining MMR | 100% (12 of 12) | - ELVN-001 remained well-tolerated across all evaluated doses and its achieved MMR rate by 24 weeks (**32%**) compared favorably with historical data from asciminib (**24-25%**) in less heavily pretreated patients[3](index=3&type=chunk) [Future Development Plans](index=2&type=section&id=2.3%20Future%20Development%20Plans) Following positive Phase 1 results, Enliven Therapeutics plans to initiate a Phase 3 pivotal trial for ELVN-001 in 2026 - The Company plans to initiate a Phase 3 pivotal trial for ELVN-001 in **2026**[4](index=4&type=chunk) [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) This section presents Enliven Therapeutics' financial performance for Q2 2025, highlighting cash position, operating expenses, and net loss [Key Financial Highlights](index=2&type=section&id=3.1%20Key%20Financial%20Highlights) Enliven Therapeutics reported a strong cash position of $490.5 million as of June 30, 2025, extending its cash runway into the first half of 2029, with increased operating expenses and net loss Cash Position (as of June 30, 2025) | Metric | Value | | :------------------------------------ | :------------ | | Cash, cash equivalents, and marketable securities | $490.5 million | | Expected cash runway | Into the first half of 2029 | Operating Expenses (Three Months Ended June 30) | Expense Category | Q2 2025 (Millions) | Q2 2024 (Millions) | YoY Change | | :----------------- | :----------------- | :----------------- | :--------- | | Research and development | $21.5 | $18.8 | +14.4% | | General and administrative | $7.1 | $5.8 | +22.4% | Net Loss (Three Months Ended June 30) | Metric | Q2 2025 (Millions) | Q2 2024 (Millions) | YoY Change | | :------- | :----------------- | :----------------- | :--------- | | Net Loss | $(25.3) | $(20.0) | +26.5% | [Condensed Consolidated Financial Information](index=4&type=section&id=3.2%20Condensed%20Consolidated%20Financial%20Information) The condensed consolidated financial statements detail Enliven's Q2 2025 performance, showing increased operating expenses, net losses, and a significant rise in cash and total assets due to recent financing [Statements of Operations](index=4&type=section&id=3.2.1%20Statements%20of%20Operations) For Q2 2025, total operating expenses increased to $28.6 million, resulting in a net loss of $25.3 million, or $(0.49) per share, with similar trends for the six-month period Statements of Operations (in thousands, except per share data) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $21,491 | $18,826 | $46,386 | $38,796 | | General and administrative | $7,093 | $5,777 | $13,891 | $11,794 | | Total operating expenses | $28,584 | $24,603 | $60,277 | $50,590 | | Loss from operations | $(28,584) | $(24,603) | $(60,277) | $(50,590) | | Other income (expense), net | $3,249 | $4,653 | $6,398 | $7,902 | | Net loss | $(25,335) | $(19,950) | $(53,879) | $(42,688) | | Net loss per share, basic and diluted | $(0.49) | $(0.41) | $(1.05) | $(0.95) | | Weighted-average shares outstanding | 52,105 | 48,075 | 51,084 | 45,060 | [Balance Sheets](index=4&type=section&id=3.2.2%20Balance%20Sheets) As of June 30, 2025, cash, cash equivalents, and marketable securities significantly increased to $490.5 million, driving total assets to $503.9 million, while liabilities remained stable and stockholders' equity grew Balance Sheet Highlights (in thousands) | Metric | June 30, 2025 | December 31, 2024 | | :------------------------------------ | :-------------- | :---------------- | | Cash, cash equivalents and marketable securities | $490,503 | $313,440 | | Total current assets | $495,622 | $318,127 | | Total assets | $503,887 | $325,760 | | Total current liabilities | $15,211 | $15,915 | | Total liabilities | $15,415 | $15,915 | | Stockholders' equity | $488,472 | $309,845 | | Total liabilities and stockholders' equity | $503,887 | $325,760 | [About Enliven Therapeutics](index=2&type=section&id=About%20Enliven%20Therapeutics) This section provides an overview of Enliven Therapeutics, detailing its focus on precision oncology and small molecule therapeutics [Company Profile](index=2&type=section&id=4.1%20Company%20Profile) Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics with a precision oncology approach to address unmet medical needs - Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics[6](index=6&type=chunk) - The company aims to address existing and emerging unmet needs with a precision oncology approach to improve survival and enhance overall well-being[6](index=6&type=chunk) - Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies[6](index=6&type=chunk) [Legal and Disclaimers](index=2&type=section&id=Legal%20and%20Disclaimers) This section outlines important legal considerations, including forward-looking statements and disclaimers regarding cross-trial comparisons [Forward-Looking Statements](index=2&type=section&id=5.1%20Forward-Looking%20Statements) This section outlines that the press release contains forward-looking statements regarding future plans, trends, and financial conditions, which are subject to substantial risks and uncertainties - The press release contains forward-looking statements concerning Enliven and other matters that involve substantial risks and uncertainties, including goals, intentions, and expectations for future plans, trends, events, results of operations, and financial condition[7](index=7&type=chunk) - Forward-looking statements are based on current beliefs and assumptions subject to risks and uncertainties, and actual results could differ materially due to factors such as limited operating history, ability to advance product candidates, regulatory approval, and intellectual property protection[7](index=7&type=chunk)[9](index=9&type=chunk) - Enliven undertakes no obligation to revise or update any forward-looking statement, except as required by applicable law[9](index=9&type=chunk) [Cross-Trial Comparison Disclaimer](index=3&type=section&id=5.2%20Cross-Trial%20Comparison%20Disclaimer) The company explicitly states that it has not performed any head-to-head trials for ELVN-001, thus cross-trial comparisons with data from different studies are not valid - The Company has not performed any head-to-head trials for ELVN-001[11](index=11&type=chunk) - Data referenced from different clinical trials at different points in time, with differences in trial design and patient populations, means conclusions from cross-trial comparisons cannot be made[11](index=11&type=chunk) [Contact Information](index=3&type=section&id=Contact%20Information) This section provides contact details for investor and media relations [Investor and Media Relations](index=3&type=section&id=6.1%20Investor%20and%20Media%20Relations) Contact information for investor and media inquiries is provided - Investors can contact ir@enliventherapeutics.com[11](index=11&type=chunk) - Media can contact media@enliventtherapeutics.com[11](index=11&type=chunk)

Core Insights - Enliven Therapeutics announced positive Phase 1 clinical trial data for ELVN-001 in chronic myeloid leukemia (CML), with a cumulative major molecular response (MMR) rate of 47% and 32% of patients achieving MMR by 24 weeks, alongside a favorable safety profile [1][2][7] - The company has a strong financial position with $491 million in cash and equivalents, expected to sustain operations into the first half of 2029 [1][2][7] Pipeline Updates - ELVN-001 is a selective small molecule kinase inhibitor targeting the BCR::ABL gene fusion, which is crucial for CML patients [3] - The company plans to initiate a Phase 3 pivotal trial for ELVN-001 in 2026, building on the positive findings from the Phase 1 trial [2][7] Financial Results - For Q2 2025, Enliven reported R&D expenses of $21.5 million, up from $18.8 million in Q2 2024, and G&A expenses of $7.1 million, compared to $5.8 million in the same period last year [7][11] - The net loss for Q2 2025 was $25.3 million, compared to a net loss of $20.0 million in Q2 2024 [7][11] Balance Sheet Highlights - As of June 30, 2025, the company had total current assets of $495.6 million, including cash, cash equivalents, and marketable securities of $490.5 million [12] - Stockholders' equity stood at $488.5 million, reflecting a significant increase from $309.8 million at the end of 2024 [12]

Group 1 - Enliven Therapeutics, Inc. (ELVN) shares have increased by 8.2% over the past four weeks, closing at $23.34, with a mean price target of $41 indicating a potential upside of 75.7% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $6.74, where the lowest estimate of $33.00 suggests a 41.4% increase, and the highest estimate of $52.00 indicates a potential surge of 122.8% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as the Zacks Consensus Estimate for the current year has risen by 4.6% over the past month [11][12] Group 2 - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside [13] - While consensus price targets may not be reliable indicators of the extent of gains, they can provide a directional guide for price movement [14]